The FDA has notified healthcare professionals of new pediatric dosing recommendations for Valcyte (valganciclovir hydrochloride, from Roche) tablets and oral solution. The pediatric dose of Valcyte is ...
Roche has presented impressive new data for its marketed antiviral Valcyte in the wake of the failure of a potential rival product, ViroPharma’s maribavir, in a late-stage study. Roche has presented ...
Roche has inked a deal with the Medicines Patent Pool to improve access to Valcyte, the Swiss major's drug to treat cytomegalovirus. Roche has inked a deal with the Medicines Patent Pool to improve ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved ...
The FDA has approved Valcyte (valganciclovir hydrochloride [prodrug of ganciclovir], from Roche) for the prevention of cytomegalovirus (CMV) disease in pediatric kidney and heart transplant patients ...
CMV is the most serious viral infection affecting transplant patients BOSTON, June 1 /PRNewswire/ -- New Phase III study results presented for the first time today at the ninth annual American ...
18 May 2004, Basel, Switzerland - Data presented at the American Transplant Congress (ATC) annual meeting show that the gold standard CMV antiviral ganciclovir (Valcyte/Cymevene) has been proven to ...
The U.S. Food and Drug Administration (FDA) has revoked a tentative approval for India's Ranbaxy Laboratories to make a cheap copy of AstraZeneca's heartburn drug Nexium, after its Indian plants were ...
Roche's antiviral drug Valcyte (valganciclovir) received confirmation that the Mutual Recognition Procedure has been completed for the prevention of cytomegalovirus (CMV) disease. CMV is a potentially ...
Archana Shanker and Nupur Maithani of Anand and Anand consider what the battle over the Valcyte patent reveals about the Indian judiciary’s approach to pharmaceutical patents F Hoffmann-La Roche, the ...
Ranbaxy welcomed a ruling by a US district court that said the company’s generic version of anti-viral drug Valcyte did not infringe Swiss pharma major Roche’s patent. The court, however, held Roche s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results